Company Profile

Akouos Inc. precision genetic medicine company focused on developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals. The Company is focused on developing precision therapies for forms of sensorineural hearing loss. The Company's genetic medicine platform that incorporates a proprietary vector library consisting of variants of a small virus commonly used in gene therapy, known as adeno-associated virus (AAV), and a novel delivery approach. The Company is focused on executing its initiatives, which include the advancement of its lead product candidate, AK-OTOF, is a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene; expansion of its pipeline to include programs focused on other monogenic conditions as well as inner ear conditions of complex etiology, such as AK-antiVEGF for vestibular schwannoma; and development of internal manufacturing capabilities, and a commercial infrastructure.

Employees

103

Sector

Biotechnology & Medical Research

More about the company

23/24/23	Akouos, Inc. Announces Positive Initial Clinical Results from the Phase 1/2 AK-OTOF-101 Study	CI
02/22/02	Akouos, Inc. Announces Executive and Board Changes	CI
01/22/01	Lilly Wraps Up Acquisition of Akouos	MT
01/22/01	Akouos, Inc.(NasdaqGS:AKUS) dropped from NASDAQ Composite Index	CI
01/22/01	Eli Lilly and Company completed the acquisition of Akouos, Inc. from a group of shareholders.	CI
30/22/30	Eli Lilly's Buyout Offer Accepted by 81% Akouos Shareholders at Closing	MT
30/22/30	Akouos, Inc.(NasdaqGS:AKUS) dropped from S&P TMI Index	CI
29/22/29	Akouos, Inc.(NasdaqGS:AKUS) dropped from NASDAQ Biotechnology Index	CI
14/22/14	Akouos Q3 Loss Narrows	MT
14/22/14	Akouos, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
19/22/19	Piper Sandler Downgrades Akouos to Neutral From Overweight, Adjusts Price Target to $13 From $18	MT
19/22/19	William Blair Downgrades Akouos to Market Perform From Outperform	MT
19/22/19	Health Care Up Amid Earnings, Deals -- Health Care Roundup	DJ

19/22/19	Piper Sandler Downgrades Akouos to Neutral From Overweight, Adjusts Price Target to $13 From $18	MT
19/22/19	William Blair Downgrades Akouos to Market Perform From Outperform	MT
18/22/18	HC Wainwright Downgrades Akouos to Neutral from Buy	MT
29/22/29	William Blair Starts Akouos at Outperform	MT
18/22/18	Piper Sandler Adjusts Akouos' Price Target to $18 From $40, Reiterates Overweight Rating	MT

02/22/02	AKOUOS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
30/22/30	Lilly and Akouos Announce Expiration of Akouos Tender Offer	PR
14/22/14	AKOUOS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
14/22/14	AKOUOS, INC. : Results of Operations and Financial Condition (form 8-K)	AQ
14/22/14	Akouos Reports Third Quarter 2022 Financial Results and Provides Business Highlights	AQ

01/22/01	Eli Lilly : a finalisé l'acquisition d'Akouos
30/22/30	Eli Lilly : vers l'acquisition de 81.1% des actions d'Akouos
19/22/19	Wall Street sluit hoger
19/22/19	Wall Street houdt winst vast
18/22/18	MÄRKTE USA/Börsen setzen Erholung fort

Manager	Title	Age	Since
Emmanuel J. Simons CEO	Chief Executive Officer	43	01/01/2016
Jean Phillips CTO	Chief Tech/Sci/R&D Officer	-	-
Aaron Tward CTO	Chief Tech/Sci/R&D Officer	-	10/03/2022

AKOUOS Share Price

Stocks

AKUS

US00973J1016

Biotechnology & Medical Research

Latest news : AKOUOS

Analysts' recommendations: AKOUOS

Press Releases: AKOUOS

News in other languages: AKOUOS

Quotes and Performance

Managers and Directors: AKOUOS

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
01/22/01	Vicki Sato	Issuer sale	Director	55,030	0.1489%
01/22/01	Sachiyo Minegishi	Issuer sale	Chief Financial Officer	1,50,000	0.4060%
01/22/01	Sona Saira Ramasastry	Issuer sale	Director	16,000	0.0433%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AKOUOS	+1.06%	+0.91%	-	-	49Cr
ARGENX SE	+1.03%	+2.30%	+55.91%	+114.22%	5.64TCr
WUXI APPTEC CO., LTD.	+2.72%	+3.26%	+46.05%	+44.91%	4.45TCr
BIONTECH SE	+1.12%	+2.79%	-15.04%	-21.68%	2.29TCr
INSMED INCORPORATED	+1.17%	+3.85%	-0.89%	+403.86%	2.12TCr
WUXI BIOLOGICS (CAYMAN) INC.	+3.81%	-5.07%	+11.00%	-30.62%	1.64TCr
GENMAB A/S	+0.15%	+2.24%	+9.32%	-39.30%	1.54TCr
EXELIXIS, INC.	-0.69%	+0.82%	+27.75%	+176.72%	1.34TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+5.27%	+5.54%	+19.65%	-	1.24TCr
PHARMAESSENTIA CORPORATION	+1.61%	+1.28%	+95.75%	+205.26%	1.12TCr
Average	+1.72%	+2.09%	+27.72%	+106.67%	2.37TCr
Weighted average by Cap.	+1.72%	+2.37%	+32.04%	+99.60%